A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Trial Profile

A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs LV 305 (Primary)
  • Indications Breast cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 1 Dec 2018 to 11 Aug 2020.
    • 08 Jun 2016 According to an Immune design media release, the company announced updated results of patients (n=24) with advanced or metastatic sarcoma cancers and the data was presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top